- Home
- RARE vs WSFS Comparison
RARE vs WSFS Comparison
Compare RARE & WSFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- WSFS
- Stock Information
- Founded
- RARE 2010
- WSFS 1980
- Country
- RARE United States
- WSFS United States
- Employees
- RARE N/A
- WSFS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- WSFS Major Banks
- Sector
- RARE Health Care
- WSFS Finance
- Exchange
- RARE Nasdaq
- WSFS Nasdaq
- Market Cap
- RARE 3.6B
- WSFS 3.3B
- IPO Year
- RARE 2014
- WSFS N/A
- Fundamental
- Price
- RARE $33.84
- WSFS $52.13
- Analyst Decision
- RARE Strong Buy
- WSFS Hold
- Analyst Count
- RARE 15
- WSFS 4
- Target Price
- RARE $95.93
- WSFS $63.67
- AVG Volume (30 Days)
- RARE 748.6K
- WSFS 365.5K
- Earning Date
- RARE 05-01-2025
- WSFS 04-24-2025
- Dividend Yield
- RARE N/A
- WSFS 1.15%
- EPS Growth
- RARE N/A
- WSFS 0.23
- EPS
- RARE N/A
- WSFS 4.41
- Revenue
- RARE $560,230,000.00
- WSFS $984,948,000.00
- Revenue This Year
- RARE $19.15
- WSFS N/A
- Revenue Next Year
- RARE $32.11
- WSFS $4.04
- P/E Ratio
- RARE N/A
- WSFS $11.81
- Revenue Growth
- RARE 29.01
- WSFS 6.26
- 52 Week Low
- RARE $33.69
- WSFS $41.33
- 52 Week High
- RARE $60.37
- WSFS $62.75
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- WSFS 45.94
- Support Level
- RARE $36.71
- WSFS $50.89
- Resistance Level
- RARE $39.21
- WSFS $53.82
- Average True Range (ATR)
- RARE 1.34
- WSFS 1.22
- MACD
- RARE -0.32
- WSFS 0.13
- Stochastic Oscillator
- RARE 2.19
- WSFS 48.00
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About WSFS WSFS Financial Corporation
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.